Tandem Diabetes Care makes insulin pumps and related diabetes technology for people with insulin-dependent diabetes. TNDM reports earnings on Thu, Nov 5, 2026. Analyst consensus is Buy, based on the latest ratings from 4 firms (2 buy, 2 hold, 0 sell).
Prices, price targets and earnings estimates for TNDM are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
Each firm's latest rating on TNDM in the past 90 days
Average 12-month target
Price targets for TNDMThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plansSign in
Latest rating changes
BarclaysInitiated
Oct 7Hold
CitigroupTarget lowered
Sep 30Hold
Truist SecuritiesTarget lowered
Sep 24Buy
CitigroupTarget raised
Aug 7Hold
RBC CapitalMaintained
Aug 7Buy
Date
Firm
Action
Rating
Price target
Oct 7
Barclays
Initiated
Hold
Sep 30
Citigroup
Target lowered
Hold
Sep 24
Truist Securities
Target lowered
Buy
Aug 7
Citigroup
Target raised
Hold
Aug 7
RBC Capital
Maintained
Buy
Loading…
Whale Options Flow
90D
No whale options trades in TNDM in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TNDM is in one of them and how their past TNDM trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Tandem Diabetes Care
Tandem Diabetes Care is a San Diego, California company that designs, develops and sells insulin delivery systems for people with diabetes. Its main products are insulin pumps, including the t:slim X2 and Mobi, along with single use supplies that connect to them. The company also offers software tools, such as Tandem Source, a data platform for users, caregivers and healthcare providers, and the Sugarmate app. Its customers are mainly people with type 1 diabetes and, in the United States, people with type 2 diabetes who need intensive insulin therapy.
